Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 1, 2007, Pages 3-11

  Kluger, Gerhard ^a   Bauer, Bettina ^b  

^a Epillepsiezentrum für Kinder und Jugendliche   (Germany)

^b Eisai GmbH   (Germany)

Author keywords

Antiepileptic drug; Lennox Gastaut syndrome; Pediatrics; Rufinamide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CINROMIDE; CYTOCHROME P450; FELBAMATE; GAMMA BUTYROLACTONE GAMMA CARBONYLHISTIDYLPROLINAMIDE CITRATE; LAMOTRIGINE; MESTRANOL PLUS NORETHISTERONE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RUFINAMIDE; TOPIRAMATE; TRIAZOLE DERIVATIVE; VALPROIC ACID;

ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ARTICLE; ATAXIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYDROLYSIS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLAUCOMA; HUMAN; HYPERTHERMIA; LENNOX GASTAUT SYNDROME; LETHARGY; LIVER FAILURE; LONG TERM CARE; LOW DRUG DOSE; MENTAL DISEASE; META ANALYSIS; METABOLIC ACIDOSIS; NAUSEA; NONHUMAN; PANCREATITIS; PSYCHOMOTOR DISORDER; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TONIC SEIZURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 34249333895     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.1.3     Document Type: Article

References (43)

1. Akalin F, Tirtir A, Yilmaz Y. 2003. Increased QT dispersion in epileptic children. Acta Paediatr, 92:916-20.
2. Anonymous. 1989. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Epilepsia, 30:422-9.
3. Anonymous. 1993. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox Gastaut syndrome. N Engl J Med, 328:29-33.
4. Bialer M, Johannessen SI, Kupferberg HJ, et al. 1996. Progress report on new antiepileptic drugs: a summary of the third Eilat conference. Epilepsy Res, 25:299-319.
5. Bialer M, Johannessen SI, Kupferberg HJ, et al. 1999. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference. Epilepsy Res, 34(1):1-41.
6. Bialer M, Johannessen SI, Kupferberg HJ, et al. 2001. Progress report on new antiepileptic drugs: a summary of the fifth Eilat conference. Epilepsy Res, 43:11-58.
7. Borowicz KK, Piskorska B, Kimber-Trojnar Z, et al. 2004. Is there any future for felbamate treatment? Pol J Pharmacol, 56:289-94.
8. Brunner LA, Harrigan EP, John VA, Powell ML. 1994. Pharmacokinetics of a new anticonvulsant. (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400-1200 mg. Am J Ther, 1:215-20.
9. Cardot JM, Lecaillon JB, Czendlik C, et al. 1998. The influence of food on the disposition of the antiepileptic nifinamide in healthy volunteers. Biopharm Drug Dispos, 19:259-62.
10. Chang SW, Choi L, Karoplchyk MA. 1998. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects [abstract]. Epilepsia, 39(Suppl 6):59 (2.110).
11. Cheung WK, Kianifard F, Wong A, et al. 1995. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res, 12:1878-82.
12. Committee on Safety of Medicines. 1996. Current problems in pharmacovigilance. Reminder Lamotrigine (Lamictal) and serious skin reactions [online]. Accessed 21 June 2006. URL: http://www.mhra.gov.uk/ home/groups/pl-p/documents/publication/con2023237.pdf.
13. Critchley D, Fuseau E, Perdomo C, Arroyo S. 2005. Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut Syndrome [abstract]. Epilepsia, 46(Suppl 7):2.351.
14. Dulac O, Engel J. Lennox-Gastaut Syndrome. 2003. Report of the International League against Epilepsy (updated 23 August 2003) [online]. Accessed 21 June 2006. URL: http://www.ilae-epilepsy.org/ctf/ lennox_gastaut.html.
15. Eisai Co Ltd. 2005. Annual Report 2005 [online]. Accessed 21 June 2006. URL: http://www.eisai.co.jp/pdf/eannual/epdf200504an.pdf
16. FDA document T94-46. 1994. Felbatol update [online]. 27 September 1994. Accessed 21 June 2006. URL: http://www.fda.gov/bbs/topics/ANSWERS/ ANS00605.html.
17. FDA 'Dear Doctor' letter. 1997. [online]. Accessed 21 June 2006. URL: http://www.fda.gov/medwatch/safety/1997/lamict.htm.
18. FDA 'Dear Doctor' letter. 2003. [online]. Accessed 21 June 2006. URL: http://www.fda.gov/medwatch/SAFETY/2003/topamax.htm.
19. French JA, Kanner AM, Bautista J, et al. 2004. Efficacy and tolerability of the new antiepiteptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society [online]. Neurology, 62(8):1261-73. Accessed 21 June 2006. URL: http://www.neurology.org/cgi/content/full/62/ 8/1261.
20. Fuseau E, Critchley D, Perdomo C, Arroyo S. 2005. Population pharmacokinetic drug-drug interaction analyses of rufinamide studies in patients with epilepsy [abstract]. Epilepsia, 46(Suppl 8):2.356.
21. Glauser TA, Kluger G, Sachdeo R, et al. 2005a. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut Syndrome (LGS): A multicenter, randomized, double-blind, placebo-controlled parallel trial [abstract]. Neurology, 64(10):1862 (LBS.001).
22. Glauser T, Kluger G, Sachdeo R, et al. 2005b. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome [abstract]. Epilepsia, 46(Suppl 6):408(1356).
23. Guerrini R. 2006. Epilepsy in children. Lancet, 367(9509):499-524.
24. Hancock E, Cross H. 2003. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev, 3:CD003277.
25. Inanaga K, Kumashiro H, Fukyama Y, et al. 1989. Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy. Epilepsia, 30:438-45.
26. Janssen-Cilag Ltd. 2006. Topamax® [online]. High Wycombe, UK. 20 January 2006. Accessed 21 June 2006. URL: http://emc.medicines.org.uk/ emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=6768.
27. Kapeghian JC, Madan A, Parkinson A, et al. 1996. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro [abstract]. Epilepsia, 37(Suppl 5):26 (1.96).
28. Kluger G, Glauser T, Sachdeo R. et al. 2006. Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Poster presented at the 7th European Congress on Epileptology, Helsinki, Finland, 2-6 July 2006.
29. Krauss GL, Perdomo C, Arroyo S. 2005. Short-term and long-term safety of rufinamide in patients with epilepsy [abstract]. Epilepsia, 46(Suppl 7):2.363.
30. Levy RH, Manson RH, Meldrurn BS, Perucca E (eds). 2002a. In Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams and Wilkins. p 906-12.
31. Levy RH, Manson RH, Meldrum BS, Perucca E (eds). 2002b. In Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams and Wilkins. p 206-14.
32. Levy RH, Manson RH, Meldrum BS, Perucca E (eds). 2002c. In Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams and Wilkins. p 760-764.
33. McLean MJ, Schmutz M, Pozza M, et al. 2005. The Influence of rufinamide on sodium currents and action potential firing in rodent neurons [abstract]. Epilepsia, 46(Suppl 7):3.062.
34. Marchand M, Critchley D, Nagy C, Fuseau E. 2005. The effect of rufinamide concentration on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PKPD analysis. Abstract presented at the Annual Meeting of the Population Approach Group in Europe 2005 [online]; (A785). Accessed 21 June 2006. URL: http://www.page-meeting.org/default.asp?abstract=785.
35. Markand ON. 2003. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol, 20:42641.
36. Motte J, Trevathan E, Arvidsson JF, et al. 1997. Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med, 337:1807-12.
37. Nabbout R, Dulac O. 2003. Epileptic encephalopathies: a brief overview. J Clin Neurophysiol, 20:393-7.
38. Sachdeo RC, Rosenfeld WE, Choi L, et al. 1998. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy [abstract]. Epilepsia, 39(Suppl 6):166-7 (5.081).
39. Sachdeo RC, Glauser TA, Ritter F, et al. 1999. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology, 52:1882-7.
40. Schmidt D, Bourgeois B. 2000. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf, 22:467-77.
41. Svendsen KD, Choi L, Chen BL, et al. 1998. Single center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women [abstract]. Epilepsia, 39(Suppl 6):59 (2.111).
42. Waldmeier F, Gschwind H-P, Rouan M-C, et al. 1996. Metabolism of the new anticonvulsive trial drug rulinamide (CGP 33101) in healthy male volunteers [abstract]. Epilepsia, 37(Suppl 5):167 (6.60).
43. White, S, Schmutz, M, Pozza, M, et al. 2005. The anticonvulsant profile and tolerability of rufinamide in mice and rats [abstract), Epilepsia, 46(Suppl 7):3.088.